Drug Trial Radar · NCT03272347
Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
Last checked: Nov 19, 2026Latest source record: Mar 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
123
Actual
Start
Nov 27, 2017
Primary completion
Mar 8, 2021
Study completion Mar 9, 2022
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Sep 5, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, antiretroviral activity, and pharmacokinetics of 3 doses of islatravir (MK-8591) in combination with doravirine (DOR) and lamivudine (3TC) administered to antiretroviral treatment-naïve adult participants with human immunodeficiency virus type 1 (HIV-1) infection.
Conditions
- HIV-1 Infection
Interventions
IslatravirDrug
Islatravir at 0.25 mg, 0.75 mg or 2.25 mg is orally administered QD in capsule form for up to 52 weeks. After Week 60 a selected open label dose may be administered.
Placebo to IslatravirDrug
Placebo to islatravir is orally administered QD in capsule form for up to 52 weeks
DoravirineDrug
Doravirine 100 mg is orally administered QD in tablet form for up to 144 weeks
Placebo to DoravirineDrug
Placebo to Doravirine is orally administered QD in tablet form for up to 52 weeks
LamivudineDrug
Lamivudine 300 mg is orally administered QD in tablet form for up to 52 weeks
Placebo to LamivudineDrug
Placebo to Lamivudine is orally administered QD in tablet form for up to 52 weeks
Doravirine/Lamivudine/Tenofovir Disoproxil FumarateDrug
Fixed dose combination of 100 mg doravirine + 300 mg lamivudine + 300 mg tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 144 weeks.
Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil FumarateDrug
Placebo to doravirine/lamivudine/tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 52 weeks
Doravirine/IslatravirDrug
Fixed dose combination of islatravir 0.75 mg/doravirine 100 mg orally administered QD in tablet form for 48 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 24Time frame: Week 24
- Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48Time frame: Week 48
- Number of Participants Experiencing Adverse Events (AEs) up to Week 144Time frame: Up to 144 weeks
- Number of Participants Discontinuing Study Drug Due to AEs up to Week 144Time frame: Up to 144 weeks
Locations
26 sites in 4 countries. Site status is shown where the registry gives one.
Pueblo Family Physicians ( Site 0119)
Phoenix, Arizona
University California / Davis ( Site 0101)
Sacramento, California
Whitman Walker Clinic ( Site 0108)
Washington D.C., District of Columbia
Orlando Immunology Center (OIC) ( Site 0105)
Orlando, Florida
Northstar Medical Center ( Site 0102)
Chicago, Illinois
Kansas City CARE Clinic ( Site 0106)
Kansas City, Missouri
Saint Hope Foundation, Inc. ( Site 0116)
Bellaire, Texas
North Texas Infectious Diseases Consultants, PA ( Site 0103)
Dallas, Texas
Tarrant County Infectious Disease Associates ( Site 0112)
Fort Worth, Texas
The Crofoot Research Center, Inc. ( Site 0118)
Houston, Texas
Biomedica Research Group ( Site 0202)
Santiago, Chile
Hospital Dr. Hernan Henriquez Aravena ( Site 0203)
Temuco, Chile
Clinica Arauco Salud ( Site 0200)
Santiago, RM, Chile
Hopital Avicenne ( Site 2302)
Bobigny, France
Hopital Saint-Andre ( Site 2307)
Bordeaux, France
CHU Hotel Dieu ( Site 2308)
Nantes, France
CHU de Nice Hopital Archet 1 ( Site 2303)
Nice, France
Hopital Bichat - Claude Bernard ( Site 2309)
Paris, France
Hopital Pitie Salpetriere ( Site 2305)
Paris, France
Hopital Saint Louis ( Site 2306)
Paris, France
Centre Hospitalier de Tourcoing ( Site 2301)
Tourcoing, France
Chelsea and Westminster Hospital ( Site 2101)
London, United Kingdom
Royal London Hospital ( Site 2103)
London, United Kingdom
The Royal Free London NHS Foundation Trust ( Site 2102)
London, United Kingdom
North Manchester General Hospital ( Site 2104)
Manchester, United Kingdom
Brighton and Sussex University Hospitals NHS Trust ( Site 2105)
Brighton, East Sussex, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.